Funding for TB and Neglected Disease Research Must Increase to Realize Promise of New Technologies
Statement from TB Alliance on release of the G-FINDER 2024 Neglected Disease R&D Report NEW YORK (January 29, 2025)—The G-FINDER 2024 Neglected
R&D News
New Clinical Trial Examines Use of Novel Compound Telacebec in Buruli Ulcer Patients
NEW YORK (August 21, 2024) – In July 2024, a Phase 2 proof-of-concept study was initiated to explore the use
News
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that
SimpliciTB Trial Results Presented at CROI 2023
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference.
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
SEONGNAM-SI, South Korea and NEW YORK, US. Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development
TaBriX and The University of Manchester are working with TB Alliance to develop novel drugs to treat drug-resistant tuberculosis
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs
News
Advancing Clinical Research Capacity in Europe: Almari Conradie on TBAJ-587 and the ERA4TB Project
TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis
TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
New results from operational research in Ukraine and MSF’s TB-PRACTECAL study on drug-resistant forms of tuberculosis to be presented PRETORIA